(R)-tert-butyl 4-(4-benzyl-2-oxooxazolidin-3-yl)-4-oxobutanoate | 865704-46-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (R)-tert-butyl 4-(4-benzyl-2-oxooxazolidin-3-yl)-4-oxobutanoate
• 英文别名: tert-butyl 4-[(4R)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]-4-oxobutanoate
• CAS: 865704-46-7
• 化学式: C₁₈H₂₃NO₅
• 分子量: 333.384
• InChiKey: MKYBLBFBODKITA-CQSZACIVSA-N

物化性质

• 熔点：
  56.5-58 °C(Solvent: Toluene ; Ligroine)
• 沸点：
  486.3±28.0 °C(Predicted)
• 密度：
  1.193±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl 4-(4-benzyl-2-oxooxazolidin-3-yl)-4-oxobutanoate 在 sodium hexamethyldisilazane 、 三氟乙酸 、 sodium iodide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 (3S)-3-{[(4R)-4-benzyl-2-oxo-1,3-oxazolidin-3-yl]carbonyl}-5-(benzyloxy)-5-oxopentanoic acid
  参考文献：
  名称：

  手性琥珀酸盐：对映体纯 β2-氨基酸的前体

  摘要：

  从常见的手性前体叔丁基琥珀酰恶唑烷酮合成了五种适当保护的对映体纯 β(2)-氨基酸，蛋白质 α-氨基酸的同系物。

  DOI：

  10.1055/s-2005-865362
• 作为产物：
  描述：

  (R)-4-苄基-2-噁唑烷酮 在 正丁基锂 、 四磷十氧化物 作用下， 以 四氢呋喃 、 正己烷 、 氯仿 为溶剂， 反应 60.5h， 生成 (R)-tert-butyl 4-(4-benzyl-2-oxooxazolidin-3-yl)-4-oxobutanoate
  参考文献：
  名称：

  Conjugates of Modified Cryptophycins and RGD-Peptides Enter Target Cells by Endocytosis

  摘要：

  Tumor targeting anticancer drug conjugates that contain a tumor recognition motif (homing device) are of high current relevance. Cryptophycins, naturally occurring cytotoxic cyclo-depsipeptides, have been modified by total synthesis to provide analogues suitable for conjugation to peptide-based homing devices. An array of functionalized beta(2)-amino acids was synthesized and incorporated into cryptophycins. All analogues proved to be highly active in the cytotoxicity assay using the human cervix carcinoma cell line KB-3-1 and its multidrug-resistant subclone KB-V1. Conformational analysis of cryptophycin-52 and two synthetic analogues was performed by NMR and MD methods to obtain information on the influence of the unit C configuration on the overall conformation. An azide-functionalized cryptophycin was connected by CuAAC to an alkyne-containing fluorescently labeled cyclic RGD-peptide as the homing device for internalization studies. Confocal fluorescence microscopy proved integrin-mediated internalization by endocytosis and final lysosomal localization of the cryptophycin prodrug.

  DOI：

  10.1021/jm301346z

文献信息

• CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：NOVARTIS AG

  公开号：US20200164024A1

  公开（公告）日：2020-05-28

  The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , X 1 , X 2 , and X 3 are described herein.

  该披露涉及对PCSK9的抑制剂，用于治疗胆固醇脂质代谢以及其他PCSK9发挥作用的疾病，其化学式为(I)： 或其药用可接受的盐、水合物、溶剂合物、前药、立体异构体、N-氧化物或互变异构体，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、X1、X2和X3如本文所述。
• A modified Curtius reaction: an efficient and simple method for direct isolation of free amine
  作者：Bin Ma、Wen-Cherng Lee

  DOI：10.1016/j.tetlet.2009.11.038

  日期：2010.1

  the corresponding primary amines. However, this reaction often requires harsh conditions for hydrolysis of the isocyanate intermediates to amines, and can also be contaminated by the formation of corresponding ureas due to the reactive nature of the intermediates. We have discovered that by quenching the isocyanate intermediates with sodium trimethylsilanolate, the free amines can be isolated after aqueous

  Curtius重排和相关的反应通常用于将羧酸转化为相应的伯胺。但是，该反应通常需要苛刻的条件才能将异氰酸酯中间体水解为胺，并且由于中间体的反应性，还可能因形成相应的脲而受到污染。我们发现，通过用三甲基硅烷醇钠淬灭异氰酸酯中间体，可以在水性处理后分离出游离胺。这种温和而快速的步骤可在一锅中以良好的产率提供游离胺。
• Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders
  申请人：NOVARTIS AG

  公开号：US11026993B2

  公开（公告）日：2021-06-08

  The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.

  本公开涉及可用于治疗胆固醇脂质代谢和 PCSK9 在其中起作用的其他疾病的 PCSK9 抑制剂，其具有式 (I)： 或其药学上可接受的盐、水合物、溶液剂、原药、立体异构体、N-氧化物或同系物，其中 R1、R1、R1、R1、R1、R1、R1、X1、X2 和 X3 在本文中描述。
• WO2020110008A5
  申请人：——

  公开号：WO2020110008A5

  公开（公告）日：2022-11-29
• CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1539766B1

  公开（公告）日：2016-12-21